Article metrics

Download PDFPDF

Original article
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

Statistics from

Online download statistics by month:

Online download statistics by month: January 2019 to October 2019

Jan 2019436428157
Feb 2019274266145
Mar 2019216209103
Apr 201912812473
May 201911110163
Jun 2019948363
Jul 2019989544
Aug 2019757237
Sep 2019868448
Oct 201911311163